Skip to main content
TLPH logo

TLPH · Talphera, Inc. · Executive Compensation

Track TLPH — free
$0.79 +0.05 (+6.25%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$40.80M
Shares
51.96M
Volume · Nov 20 357.32K Avg daily vol (3M) 144.24K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Vincent J. Angotti $1,117,277
Raffi Asadorian $727,309
Shakil Aslam $654,840
Fiscal 2024
Executive Total
Vincent J. Angotti $1,038,992
Raffi Asadorian $709,857
Badri Dasu $575,959
Shakil Aslam $529,242
Fiscal 2023
Executive Total
Vincent J. Angotti $1,211,994
Pamela Palmer $814,270
Raffi Asadorian $742,609
Badri Dasu $602,166
Fiscal 2022
Executive Total
Vincent J. Angotti $1,297,016
Pamela Palmer $822,400
Raffi Asadorian $755,144
Fiscal 2021
Executive Total
Vincent J. Angotti $2,447,954
Pamela Palmer $1,083,507
Raffi Asadorian $1,024,610
Fiscal 2020
Executive Total
Vincent J. Angotti $1,765,522
Pamela Palmer $962,122
Raffi Asadorian $890,716
Badri Dasu $686,353
Fiscal 2019
Executive Total
Vincent J. Angotti $2,125,052
Pamela Palmer $1,083,333
Raffi Asadorian $1,013,492
Badri Dasu $776,258
Lawrence G. Hamel $776,018
Fiscal 2018
Executive Total
Vincent J. Angotti $1,738,845
Pamela Palmer $1,063,956
Raffi Asadorian $907,235
Badri Dasu $734,208
Lawrence G. Hamel $688,617
Fiscal 2017
Executive Total
Vincent J. Angotti $2,353,923
Pamela Palmer $874,093
Raffi Asadorian $606,287
Badri Dasu $595,179
Lawrence G. Hamel $595,179

Executive changes

Person Change Filed
Mark Wan Appointed 2026-06-23
Joseph Todisco Appointed 2026-06-23
Marina Bozilenko Appointed 2026-06-23
Abhinav Jain Appointed 2025-10-24
Stephen J. Hoffman Appointed 2025-10-24
Vincent J. Angotti Appointed 2025-10-24
Joseph Todisco Appointed 2025-10-16
Shakil Aslam Appointed 2024-08-14
Shakil Aslam Appointed 2024-08-14
Pamela P. Palmer, MD, PhD
“Dr. Palmer's decision to resign is not the result of any dispute or disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
Resigned 2024-08-14
Jill Broadfoot Appointed 2024-06-24
Adrian Adams Appointed 2024-06-24
Howard B. Rosen
“Dr. Afable and Mr. Rosen's resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
Resigned 2024-03-01
Pamela P. Palmer, M.D., Ph.D.
“Dr. Palmer's resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
Resigned 2024-03-01
Richard Afable, M.D.
“Dr. Afable and Mr. Rosen's resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
Resigned 2024-03-01
Abhinav Jain Appointed 2024-01-22
Mark Wan Appointed 2023-10-10
Howard B. Rosen Appointed 2023-10-10
Marina Bozilenko Appointed 2023-10-10
Mark G. Edwards
“The resignation is not a result of any disagreement between Mr. Edwards and AcelRx Pharmaceuticals, Inc.”
Resigned 2022-03-01
Jill M. Broadfoot Appointed 2021-11-23
Marina Bozilenko Appointed 2021-03-31

Leadership

Key facts CIK 1427925 CUSIP 00444T209 13F (30d) 57 filings 49 filers Visit website Investor relations